These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 26700564

  • 1. Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.
    Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM.
    Mol Pharmacol; 2016 Mar; 89(3):364-75. PubMed ID: 26700564
    [Abstract] [Full Text] [Related]

  • 2. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
    Laprairie RB, Bagher AM, Kelly ME, Dupré DJ, Denovan-Wright EM.
    J Biol Chem; 2014 Sep 05; 289(36):24845-62. PubMed ID: 25037227
    [Abstract] [Full Text] [Related]

  • 3. Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that Target the Endocannabinoid Receptors in Huntington's Disease.
    Bagher AM, Laprairie RB, Kelly MEM, Denovan-Wright EM.
    Methods Mol Biol; 2018 Sep 05; 1780():549-571. PubMed ID: 29856035
    [Abstract] [Full Text] [Related]

  • 4. Antagonism of Dopamine Receptor 2 Long Affects Cannabinoid Receptor 1 Signaling in a Cell Culture Model of Striatal Medium Spiny Projection Neurons.
    Bagher AM, Laprairie RB, Kelly ME, Denovan-Wright EM.
    Mol Pharmacol; 2016 Jun 05; 89(6):652-66. PubMed ID: 27053685
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB1, CB2 and CB1/CB2 heteromer receptors.
    Navarro G, Varani K, Lillo A, Vincenzi F, Rivas-Santisteban R, Raïch I, Reyes-Resina I, Ferreiro-Vera C, Borea PA, Sánchez de Medina V, Nadal X, Franco R.
    Pharmacol Res; 2020 Sep 05; 159():104940. PubMed ID: 32470563
    [Abstract] [Full Text] [Related]

  • 6. Cannabidiol skews biased agonism at cannabinoid CB1 and CB2 receptors with smaller effect in CB1-CB2 heteroreceptor complexes.
    Navarro G, Reyes-Resina I, Rivas-Santisteban R, Sánchez de Medina V, Morales P, Casano S, Ferreiro-Vera C, Lillo A, Aguinaga D, Jagerovic N, Nadal X, Franco R.
    Biochem Pharmacol; 2018 Nov 05; 157():148-158. PubMed ID: 30194918
    [Abstract] [Full Text] [Related]

  • 7. Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: implications for Huntington's disease.
    Laprairie RB, Kelly ME, Denovan-Wright EM.
    Neuropharmacology; 2013 Sep 05; 72():47-57. PubMed ID: 23602984
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
    Dowie MJ, Bradshaw HB, Howard ML, Nicholson LF, Faull RL, Hannan AJ, Glass M.
    Neuroscience; 2009 Sep 29; 163(1):456-65. PubMed ID: 19524019
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Heteromer formation between cannabinoid type 1 and dopamine type 2 receptors is altered by combination cannabinoid and antipsychotic treatments.
    Bagher AM, Young AP, Laprairie RB, Toguri JT, Kelly MEM, Denovan-Wright EM.
    J Neurosci Res; 2020 Dec 29; 98(12):2496-2509. PubMed ID: 32881145
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice.
    Myers AM, Siegele PB, Foss JD, Tuma RF, Ward SJ.
    Br J Pharmacol; 2019 May 29; 176(10):1552-1567. PubMed ID: 29338068
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
    Rao GK, Kaminski NE.
    J Pharmacol Exp Ther; 2006 May 29; 317(2):820-9. PubMed ID: 16436496
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.